Pain Is A Harbinger Of The Last Months Of Life At Half The Elderly.
Pain is a commonly reported earmark during the pattern few years of life, with reports of cramp increasing during the final few months, a new study has shown. Just over a fourth of multitude reported being "troubled" by moderate or severe pain two years before they died, the researchers found. At four months before death, that add had jumped to nearly half. "This swotting shows that there's a substantial burden of pain at the end of life, and not just the very end of life," said the study's move author, Dr Alexander K Smith, an assistant professor of panacea at the University of California, San Francisco, and a staff physician at the San Francisco VA Medical Center.
And "Arthritis was the unique biggest predictor of pain". Results of the study are published in the Nov 2, 2010 edition of the Annals of Internal Medicine. Smith and his co-authors pointed out that numerous studies have been done on annoyance associated with specific conditions, such as cancer, but that theirs may be the first to address woe from all conditions toward the end of life, a time when most people would say that being pain-free is a priority.
The study included dope on more than 4700 people who died while participating in a study of older adults called the Health and Retirement Study. The mug up participants averaged 76 years old, included marginally more men than women and were mostly (83 percent) white. Every two years, they were asked if they were troubled by pain. If they answered yes, they were asked to classify their pain as mild, moderate or severe.
Showing posts with label months. Show all posts
Showing posts with label months. Show all posts
Wednesday 1 January 2020
Saturday 13 January 2018
New Researches In Treatment Of Rheumatoid Arthritis
New Researches In Treatment Of Rheumatoid Arthritis.
About half of rheumatoid arthritis patients stopped taking their medications within two years after they started them, a unripe office finds June 2013. Rheumatoid arthritis affects about one in 100 family worldwide and can cause radical joint destruction, deformity, pain and stiffness. The disease can reduce actual function, quality of life and life expectancy. The main reason about one-third of patients discontinued their medications was because the drugs mislaid their effectiveness, the study authors found. Other reasons included refuge concerns (20 percent), doctor preference (nearly 28 percent), resigned preference (about 18 percent) and access to treatment (9 percent), according to the bookwork results, which were presented Thursday at the annual meeting of the European League Against Rheumatism (EULAR), in Madrid, Spain.
Rheumatoid arthritis "is a growing disease, which, if left untreated, can significantly and interminably reduce joint function, patient mobility and quality of life," study lead framer Dr Vibeke Strand, a clinical professor at Stanford University School of Medicine, said in an EULAR newsflash release. "Studies have shown that patients sustain maximum benefit from rheumatoid arthritis therapy in the first two years - yet our data highlight significant discontinuation rates during this moment period".
About half of rheumatoid arthritis patients stopped taking their medications within two years after they started them, a unripe office finds June 2013. Rheumatoid arthritis affects about one in 100 family worldwide and can cause radical joint destruction, deformity, pain and stiffness. The disease can reduce actual function, quality of life and life expectancy. The main reason about one-third of patients discontinued their medications was because the drugs mislaid their effectiveness, the study authors found. Other reasons included refuge concerns (20 percent), doctor preference (nearly 28 percent), resigned preference (about 18 percent) and access to treatment (9 percent), according to the bookwork results, which were presented Thursday at the annual meeting of the European League Against Rheumatism (EULAR), in Madrid, Spain.
Rheumatoid arthritis "is a growing disease, which, if left untreated, can significantly and interminably reduce joint function, patient mobility and quality of life," study lead framer Dr Vibeke Strand, a clinical professor at Stanford University School of Medicine, said in an EULAR newsflash release. "Studies have shown that patients sustain maximum benefit from rheumatoid arthritis therapy in the first two years - yet our data highlight significant discontinuation rates during this moment period".
Saturday 16 July 2016
Children Who Were Breastfed In The Future Much Better In School
Children Who Were Breastfed In The Future Much Better In School.
Adding to reports that breast-feeding boosts perspicacity health, a uncharted scan finds that infants breast-fed for six months or longer, especially boys, do considerably better in school at majority 10 compared to bottle-fed tots, according to a new study. "Breast-feeding should be promoted for both boys and girls for its consummate benefits," said study leader Wendy Oddy, a researcher at the Telethon Institute for Child Health Research in Perth, Australia. For the study, published online Dec 20, 2010 in Pediatrics, she and her colleagues looked at the abstract scores at maturity 10 of more than a thousand children whose mothers had enrolled in an continual study in western Australia.
After adjusting for such factors as gender, kids income, maternal factors and early stimulation at home, such as reading to children, they estimated the links between breast-feeding and academic outcomes. Babies who were mainly breast-fed for six months or longer had higher erudite scores on standardized tests than those breast-fed fewer than six months, she found. But the consequence varied by gender, and the improvements were only significant from a statistical point of view for the boys.
The boys had better scores in math, reading, spelling and script if they were breast-fed six months or longer. Girls breast-fed for six months or longer had a short but statistically insignificant benefit in reading scores. The why for the gender differences is unclear, but Oddy speculates that the protective role of breast withdraw on the brain and its later consequences for language development may have greater benefits for boys because they are more vulnerable during touch-and-go development periods.
Another possibility has to do with the positive effect of breastfeeding on the mother-child relationship. "A several of studies found that boys are more reliant than girls on maternal attention and encouragement for the acquisition of cognitive and parlance skills. If breastfeeding facilitates mother-child interactions, then we would expect the positive effects of this check to be greater in males compared with females, as we observed".
Adding to reports that breast-feeding boosts perspicacity health, a uncharted scan finds that infants breast-fed for six months or longer, especially boys, do considerably better in school at majority 10 compared to bottle-fed tots, according to a new study. "Breast-feeding should be promoted for both boys and girls for its consummate benefits," said study leader Wendy Oddy, a researcher at the Telethon Institute for Child Health Research in Perth, Australia. For the study, published online Dec 20, 2010 in Pediatrics, she and her colleagues looked at the abstract scores at maturity 10 of more than a thousand children whose mothers had enrolled in an continual study in western Australia.
After adjusting for such factors as gender, kids income, maternal factors and early stimulation at home, such as reading to children, they estimated the links between breast-feeding and academic outcomes. Babies who were mainly breast-fed for six months or longer had higher erudite scores on standardized tests than those breast-fed fewer than six months, she found. But the consequence varied by gender, and the improvements were only significant from a statistical point of view for the boys.
The boys had better scores in math, reading, spelling and script if they were breast-fed six months or longer. Girls breast-fed for six months or longer had a short but statistically insignificant benefit in reading scores. The why for the gender differences is unclear, but Oddy speculates that the protective role of breast withdraw on the brain and its later consequences for language development may have greater benefits for boys because they are more vulnerable during touch-and-go development periods.
Another possibility has to do with the positive effect of breastfeeding on the mother-child relationship. "A several of studies found that boys are more reliant than girls on maternal attention and encouragement for the acquisition of cognitive and parlance skills. If breastfeeding facilitates mother-child interactions, then we would expect the positive effects of this check to be greater in males compared with females, as we observed".
Tuesday 13 October 2015
The Experimental Drug Against Lung Cancer Prolongs Patients' Lives
The Experimental Drug Against Lung Cancer Prolongs Patients' Lives.
Researchers record they prolonged survival for some patients with advanced non-small room lung cancer, for whom the median survival is currently only about six months. One ruminate on discovered that an experimental sedate called crizotinib shrank tumors in the majority of lung cancer patients with a specific gene variant. An estimated 5 percent of lung cancer patients, or brutally 40000 men and women worldwide, have this gene variant.
A second study found that a double-chemotherapy regimen benefited past it patients, who represent the majority of those with lung cancer worldwide. Roughly 100000 patients with lung cancer in the United States are over the time of 70. "This is our toughest cancer in many ways," said Dr Mark Kris, arbitrator of a Saturday press conference at the annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago. "It affects 220000 Americans each year, and over a million population worldwide. Sadly, it is our nation's - and our world's - foremost cancer".
The initial study, a phase 1 trial, found that 87 percent of 82 patients with advanced non-small chamber lung cancer with a specific mutation of the ALK gene, which makes that gene merge with another, responded robustly to treatment with crizotinib, which is made by Pfizer Inc. "The patients were treated for an unexceptional of six months, and more than 90 percent saw their tumors contract in size and 72 percent of participants remained progression-free six months after treatment," said lessons author Dr Yung-Jue Bang, a professor in the department of internal medicine at Seoul National University College of Medicine in South Korea. Ordinarily, only about 10 percent of patients would be expected to return to treatment.
About half of patients competent nausea, vomiting and diarrhea but these camp effects eased over time. The fusion gene was first discovered to play a duty in this type of lung cancer in 2007. Researchers are now working on a phase 3 trial of the drug. The Korean researchers reported economic ties to Pfizer.
Researchers record they prolonged survival for some patients with advanced non-small room lung cancer, for whom the median survival is currently only about six months. One ruminate on discovered that an experimental sedate called crizotinib shrank tumors in the majority of lung cancer patients with a specific gene variant. An estimated 5 percent of lung cancer patients, or brutally 40000 men and women worldwide, have this gene variant.
A second study found that a double-chemotherapy regimen benefited past it patients, who represent the majority of those with lung cancer worldwide. Roughly 100000 patients with lung cancer in the United States are over the time of 70. "This is our toughest cancer in many ways," said Dr Mark Kris, arbitrator of a Saturday press conference at the annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago. "It affects 220000 Americans each year, and over a million population worldwide. Sadly, it is our nation's - and our world's - foremost cancer".
The initial study, a phase 1 trial, found that 87 percent of 82 patients with advanced non-small chamber lung cancer with a specific mutation of the ALK gene, which makes that gene merge with another, responded robustly to treatment with crizotinib, which is made by Pfizer Inc. "The patients were treated for an unexceptional of six months, and more than 90 percent saw their tumors contract in size and 72 percent of participants remained progression-free six months after treatment," said lessons author Dr Yung-Jue Bang, a professor in the department of internal medicine at Seoul National University College of Medicine in South Korea. Ordinarily, only about 10 percent of patients would be expected to return to treatment.
About half of patients competent nausea, vomiting and diarrhea but these camp effects eased over time. The fusion gene was first discovered to play a duty in this type of lung cancer in 2007. Researchers are now working on a phase 3 trial of the drug. The Korean researchers reported economic ties to Pfizer.
Sunday 15 December 2013
Within 6 Months After The Death Of A Loved One Or Child Has An Increased Risk Of Heart Attack.
In the months following the extirpation of a spouse or a child, the surviving spouse or facetiousmater may sheathe a higher jeopardy of heart attack or sudden cardiac death due to an increased heart rate, budding research suggests. The risk tends to dissipate within six months, the study authors said. "While the core at the time of bereavement is naturally directed toward the deceased person, the fitness and welfare of bereaved survivors should also be of concern to medical professionals, as well as family and friends," study prima donna author Thomas Buckley, acting director of postgraduate studies at the University of Sydney Nursing School in Sydney, Australia, said in an American Heart Association announcement release.
And "Some bereaved," he added, "especially those already at increased cardiovascular risk, might better from medical review, and they should hope medical assistance for any possible cardiac symptoms". Buckley and his colleagues are scheduled to present their observations Sunday at the annual engagement of the American Heart Association, in Chicago. While prior delving has indicated that heart health may be compromised among the bereaved, it has remained unclear what exactly drives this increased chance and why the risk diminishes over time.
The new study suggests that there is a psychological dimension to the dynamic, one centered around a stand-by increase in the incidence of stress and depression. The study authors examined the exit by tracking 78 bereaved spouses and parents between the ages of 33 and 91 (55 women and 23 men) for six months, starting within the two-week age following the squandering of their child or spouse.
In the months following the extirpation of a spouse or a child, the surviving spouse or facetiousmater may sheathe a higher jeopardy of heart attack or sudden cardiac death due to an increased heart rate, budding research suggests. The risk tends to dissipate within six months, the study authors said. "While the core at the time of bereavement is naturally directed toward the deceased person, the fitness and welfare of bereaved survivors should also be of concern to medical professionals, as well as family and friends," study prima donna author Thomas Buckley, acting director of postgraduate studies at the University of Sydney Nursing School in Sydney, Australia, said in an American Heart Association announcement release.
And "Some bereaved," he added, "especially those already at increased cardiovascular risk, might better from medical review, and they should hope medical assistance for any possible cardiac symptoms". Buckley and his colleagues are scheduled to present their observations Sunday at the annual engagement of the American Heart Association, in Chicago. While prior delving has indicated that heart health may be compromised among the bereaved, it has remained unclear what exactly drives this increased chance and why the risk diminishes over time.
The new study suggests that there is a psychological dimension to the dynamic, one centered around a stand-by increase in the incidence of stress and depression. The study authors examined the exit by tracking 78 bereaved spouses and parents between the ages of 33 and 91 (55 women and 23 men) for six months, starting within the two-week age following the squandering of their child or spouse.
Sunday 3 November 2013
New Treatments For Patients With Colorectal And Liver Cancer
New Treatments For Patients With Colorectal And Liver Cancer.
For advanced colon cancer patients who have developed liver tumors, suspect "radioactive beads" implanted near these tumors may continue survival nearly a year longer than surrounded by patients on chemotherapy alone, a miserly untrained over finds. The same study, however, found that a drug commonly entranced in the months before the procedure does not increase this survival benefit penis inlargement oil outlet in abu dhabi. The research, from Beaumont Hospitals in Michigan, helps prepayment the covenant of how various treatment combinations for colorectal cancer - the third most garden-variety cancer in American men and women - attack how well each individual treatment works, experts said.
And "I unquestionably think there's a lot of room for studying the associations between extraordinary types of treatments," said study author Dr Dmitry Goldin, a radiology in residence at Beaumont. "There are constantly strange treatments, but they come out so fast that we don't always know the consequences or complications of the associations. We distress to study the sequence, or order, of treatments".
The writing-room is scheduled to be presented Saturday at the International Symposium on Endovascular Therapy in Miami Beach, Fla. Research presented at painstaking conferences has not been peer-reviewed or published and should be considered preliminary. Goldin and his colleagues reviewed medical records from 39 patients with advanced colon cancer who underwent a approach known as yttrium-90 microsphere radioembolization.
This nonsurgical treatment, approved by the US Food and Drug Administration, implants puny radioactive beads near inoperable liver tumors. Thirty of the patients were pretreated with the hallucinogen Avastin (bevacizumab) in periods ranging from less than three months to more than nine months before the radioactive beads were placed.
For advanced colon cancer patients who have developed liver tumors, suspect "radioactive beads" implanted near these tumors may continue survival nearly a year longer than surrounded by patients on chemotherapy alone, a miserly untrained over finds. The same study, however, found that a drug commonly entranced in the months before the procedure does not increase this survival benefit penis inlargement oil outlet in abu dhabi. The research, from Beaumont Hospitals in Michigan, helps prepayment the covenant of how various treatment combinations for colorectal cancer - the third most garden-variety cancer in American men and women - attack how well each individual treatment works, experts said.
And "I unquestionably think there's a lot of room for studying the associations between extraordinary types of treatments," said study author Dr Dmitry Goldin, a radiology in residence at Beaumont. "There are constantly strange treatments, but they come out so fast that we don't always know the consequences or complications of the associations. We distress to study the sequence, or order, of treatments".
The writing-room is scheduled to be presented Saturday at the International Symposium on Endovascular Therapy in Miami Beach, Fla. Research presented at painstaking conferences has not been peer-reviewed or published and should be considered preliminary. Goldin and his colleagues reviewed medical records from 39 patients with advanced colon cancer who underwent a approach known as yttrium-90 microsphere radioembolization.
This nonsurgical treatment, approved by the US Food and Drug Administration, implants puny radioactive beads near inoperable liver tumors. Thirty of the patients were pretreated with the hallucinogen Avastin (bevacizumab) in periods ranging from less than three months to more than nine months before the radioactive beads were placed.
Thursday 22 August 2013
A New Therapeutic Vaccine Against Prostate Cancer
A New Therapeutic Vaccine Against Prostate Cancer.
A newly approved curative prostate cancer vaccine won the validate Wednesday of a Medicare consultative committee, increasing the chances that Medicare will deserts for the drug. Officials from Medicare, the federal assurance program for the elderly and disabled, will believe the committee's vote when making a final decision on payment. Such a purposefulness is expected in several months, the Wall Street Journal reported bestvito. The vaccine, called Provenge and made by the Dendreon Corp, costs $93000 per unfaltering and extends survival by about four months on average, according to results from clinical trials.
A boning up published in July in the New England Journal of Medicine found that the vaccine extended the lives of men with metastatic tumors uncompliant to authoritative hormonal treatment, compared with no treatment. And the psychoanalysis interested less toxicity than chemotherapy.
Provenge is a healthy (not preventive) vaccine made from the patient's own whey-faced blood cells. Once removed from the patient, the cells are treated with the stupefy and placed back into the patient. These treated cells then trigger an insusceptible answer that in turn kills cancer cells, leaving natural cells unharmed.
The vaccine is given intravenously in a three-dose outline delivered in two-week intervals. "The strategy of trying to harness the unsusceptible system to fight cancer has been something that commonalty have tried to attain for many years; this is one such strategy," study lead researcher Dr Philip Kantoff, a professor of cure-all at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute in Boston, told HealthDay.
A newly approved curative prostate cancer vaccine won the validate Wednesday of a Medicare consultative committee, increasing the chances that Medicare will deserts for the drug. Officials from Medicare, the federal assurance program for the elderly and disabled, will believe the committee's vote when making a final decision on payment. Such a purposefulness is expected in several months, the Wall Street Journal reported bestvito. The vaccine, called Provenge and made by the Dendreon Corp, costs $93000 per unfaltering and extends survival by about four months on average, according to results from clinical trials.
A boning up published in July in the New England Journal of Medicine found that the vaccine extended the lives of men with metastatic tumors uncompliant to authoritative hormonal treatment, compared with no treatment. And the psychoanalysis interested less toxicity than chemotherapy.
Provenge is a healthy (not preventive) vaccine made from the patient's own whey-faced blood cells. Once removed from the patient, the cells are treated with the stupefy and placed back into the patient. These treated cells then trigger an insusceptible answer that in turn kills cancer cells, leaving natural cells unharmed.
The vaccine is given intravenously in a three-dose outline delivered in two-week intervals. "The strategy of trying to harness the unsusceptible system to fight cancer has been something that commonalty have tried to attain for many years; this is one such strategy," study lead researcher Dr Philip Kantoff, a professor of cure-all at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute in Boston, told HealthDay.
Subscribe to:
Posts (Atom)